Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytosis01.08.02.0010.000783%Not Available
Thrombosis24.01.01.006--Not Available
Thyroid disorder05.02.01.002--Not Available
Tongue disorder07.14.01.002--Not Available
Tonsillar hypertrophy22.04.05.0060.000313%Not Available
Tooth disorder07.09.05.001--Not Available
Toothache07.09.06.001--
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
Transplant rejection12.02.05.022; 10.02.03.0020.000313%Not Available
Trismus17.01.03.004; 15.05.04.004--
Ulcer08.03.06.0010.000940%Not Available
Umbilical hernia07.16.03.001--Not Available
Urine abnormality20.02.01.013--Not Available
Uterine cancer21.07.02.003; 16.12.05.0010.000313%Not Available
Uterine leiomyoma21.07.02.004; 16.04.02.0010.000627%Not Available
Uveitis06.04.03.003; 10.02.01.0230.000940%
Varicella23.11.05.008; 11.05.02.004--Not Available
Vasculitis24.12.04.027; 10.02.02.0060.001159%
Visual acuity reduced06.02.10.012; 17.17.01.0110.001003%
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vitamin B12 deficiency14.12.02.0040.000313%Not Available
Vitamin K deficiency14.12.03.0050.000313%Not Available
Volvulus07.13.01.0120.000470%Not Available
Vomiting07.01.07.0030.020710%
Tubulointerstitial nephritis20.05.02.0020.000627%Not Available
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.000940%Not Available
Fibromyalgia15.05.02.002--Not Available
Musculoskeletal disorder15.03.05.0250.000470%Not Available
Intestinal polyp16.05.01.002; 07.20.01.009--Not Available
Joint range of motion decreased15.01.02.006--
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene